Scientists find unexpected "benefits" of diabetes drug Linagliptin

Recipes rich in fat and refined sugar have increased the number of obese and type 2 diabetics worldwide, and menopausal women with obesity and diabetes have a greater risk of heart disease at a similar age to men at a similar age and higher risk. A study initiated by researchers at the University of Missouri School of Medicine noted that the diabetes drug Linagliptin prevented and strengthened the left ventricle of the heart in overweight female rats, a finding that could help humans, especially women, manage their cardiovascular health.
　　In previous studies, we showed that young female rats consuming a Western diet high in fat, sucrose and fructose not only gained weight but also exhibited symptoms such as vascular sclerosis, which is consistent with the results of our current trial, in which we sought to understand the role of Linagliptin in preventing heart disease," the researchers said. "
　　In this trial, the researchers divided the experimental mice into two groups, one of which was fed a normal recipe or a high-fat Western recipe daily, and the other group was fed a high-fat Western recipe with a low dose of Linagliptin for four months to observe the ability of the mice's left atrium by ultrasound.
　　The results of the experiment found that "the mice fed the Western diet had increased body weight, increased heart weight and diastolic insufficiency. However, mice on the Western diet with low doses of Linagliptin showed no signs of diastolic insufficiency, and in addition to that, they had less oxidative stress and fewer inflammatory conditions."
　　"This finding is exciting and next we will further investigate the effects of Linagliptin on important protein functions in the hope that we can contribute to the management of cardiovascular disease."